| AIRAC date | State | City | Airport | FDC No. | FDC date | Procedure name |
|---|---|---|---|---|---|---|
| 9–Jul–26 | MT | Fort Benton | Fort Benton | 6/3348 | 3/6/2026 | RNAV (GPS) RWY 23, Orig-A. |
| 9–Jul–26 | MN | Appleton | Appleton Muni | 6/3349 | 3/5/2026 | RNAV (GPS) RWY 13, Orig-B. |
| 9–Jul–26 | MI | Bad Axe | Huron County Meml | 6/3350 | 3/5/2026 | RNAV (GPS) RWY 17, Orig-B. |
| 9–Jul–26 | GA | Bainbridge | Decatur County Industrial Air Park. | 6/3351 | 3/4/2026 | RNAV (GPS) RWY 9, Amdt 1A. |
| 9–Jul–26 | TX | Big Spring | Big Spring/Mc Mahon-Wrinkle | 6/3352 | 3/5/2026 | RNAV (GPS) RWY 35, Amdt 1A. |
| 9–Jul–26 | TX | Childress | Childress Muni | 6/3353 | 3/5/2026 | VOR RWY 36, Amdt 10B. |
| 9–Jul–26 | IA | Cedar Rapids | The Eastern Iowa | 6/3359 | 3/5/2026 | RNAV (GPS) RWY 13, Amdt 1D. |
| 9–Jul–26 | OH | Wapakoneta | Neil Armstrong | 6/3371 | 3/5/2026 | RNAV (GPS) RWY 8, Orig-D. |
| 9–Jul–26 | NE | Scottsbluff | Scottsbluff/Western Nebraska Rgnl/Wm B Heilig Fld. | 6/3917 | 3/6/2026 | RNAV (GPS) RWY 12, Amdt 1A. |
| 9–Jul–26 | NE | Scottsbluff | Scottsbluff/Western Nebraska Rgnl/Wm B Heilig Fld. | 6/3919 | 3/6/2026 | RNAV (GPS) RWY 23, Orig-A. |
| 9–Jul–26 | CA | Brawley | Brawley Muni | 6/3922 | 3/6/2026 | RNAV (GPS) RWY 26, Orig-B. |
| 9–Jul–26 | NE | Ainsworth | Ainsworth Rgnl | 6/3953 | 3/6/2026 | VOR RWY 17, Amdt 3A. |
| 9–Jul–26 | TX | Houston | Houston/Southwest | 6/3957 | 3/5/2026 | RNAV (GPS) RWY 27, Amdt 1A. |
| 9–Jul–26 | AK | Togiak Village | Togiak | 6/4516 | 3/16/2026 | RNAV (GPS) RWY 3, Amdt 1. |
| 9–Jul–26 | AK | Togiak Village | Togiak | 6/4517 | 3/16/2026 | RNAV (GPS) RWY 21, Amdt 2. |
| 9–Jul–26 | AK | Koliganek | Koliganek | 6/4520 | 3/16/2026 | RNAV (GPS) RWY 9, Amdt 1A. |
| 9–Jul–26 | AK | Koliganek | Koliganek | 6/4521 | 3/16/2026 | RNAV (GPS) RWY 27, Amdt 1A. |
| 9–Jul–26 | OR | Redmond | Roberts Fld | 6/6521 | 2/24/2026 | VOR–A, Amdt 7. |
| 9–Jul–26 | CA | Calipatria | Cliff Hatfield Meml | 6/6655 | 3/16/2026 | RNAV (GPS) RWY 8, Amdt 1. |
| 9–Jul–26 | CA | Bishop | Bishop | 6/6656 | 3/16/2026 | RNAV (GPS) Z RWY 12, Orig-F. |
| 9–Jul–26 | CA | Camarillo | Camarillo | 6/6657 | 3/16/2026 | RNAV (GPS) Y RWY 26, Orig-A. |
| 9–Jul–26 | LA | Alexandria | Alexandria Intl | 6/6667 | 3/16/2026 | ILS OR LOC RWY 14, Amdt 1C. |
| 9–Jul–26 | LA | Alexandria | Alexandria Intl | 6/6672 | 3/16/2026 | RNAV (GPS) RWY 14, Amdt 1C. |
| 9–Jul–26 | NY | Ogdensburg | Ogdensburg Intl | 6/8649 | 3/16/2026 | RNAV (GPS) RWY 27, Amdt 2B. |
| 9–Jul–26 | IA | Waterloo | Waterloo Rgnl | 6/8758 | 2/23/2026 | RNAV (GPS) RWY 12, Amdt 1. |
| 9–Jul–26 | SC | Camden | Woodward Fld | 6/8781 | 3/17/2026 | RNAV (GPS) RWY 6, Orig-A. |
| 9–Jul–26 | SC | Camden | Woodward Fld | 6/8782 | 3/17/2026 | RNAV (GPS) RWY 24, Orig-A. |
| 9–Jul–26 | CA | Mammoth Lakes | Mammoth Yosemite | 6/8800 | 2/24/2026 | RNAV (GPS) RWY 27, Amdt 2. |
| 9–Jul–26 | WI | Oshkosh | Wittman Rgnl | 6/9161 | 3/17/2026 | VOR RWY 9, Amdt 10C. |
| 9–Jul–26 | WI | Oshkosh | Wittman Rgnl | 6/9163 | 3/17/2026 | VOR RWY 36, Amdt 17B. |
| 9–Jul–26 | IA | Grinnell | Grinnell Rgnl | 6/9950 | 3/18/2026 | RNAV (GPS) RWY 13, Amdt 1. |
| 9–Jul–26 | PA | Meadville | Port Meadville | 6/9951 | 3/18/2026 | RNAV (GPS) RWY 25, Amdt 1F. |

[FR Doc. 2026–10896 Filed 5–29–26; 8:45 am]

**BILLING CODE 4910–13–P**

## SECURITIES AND EXCHANGE COMMISSION

### 17 CFR Parts 240 and 249

**[Release No. 34–104903A]**

**RIN 3235–AN75**

## Holding Foreign Insiders Accountable Act Disclosure; Correction

**AGENCY:** Securities and Exchange Commission.

**ACTION:** Final rule; technical corrections.

**SUMMARY:** This document makes technical corrections to certain amendments to the Commission's disclosure rules and forms adopted in Release No. 34–104903 (February 27, 2026), which was published in the **Federal Register** on March 3, 2026. Specifically, these technical corrections remove certain language that inadvertently was included in a rule and remove obsolete references to a repealed Congressional act in two forms.

**DATES:** Effective date: June 1, 2026.

**FOR FURTHER INFORMATION CONTACT:** Kateryna Kuntsevich, Special Counsel, Office of International Corporate Finance, Division of Corporation Finance, at (202) 551–3450, Securities and Exchange Commission, 100 F Street NE, Washington, DC 20549.

**SUPPLEMENTARY INFORMATION:** This document makes technical corrections to the following rule and forms, amendments to which were published in the **Federal Register** on March 3, 2026 (91 FR 10320):

| Commission reference | CFR citation (17 CFR) |
|---|---|
| Securities Exchange Act of 1934 (''Exchange Act''): [1] | |
| Rule 16a–2 | § 240.16a–2 |
| Form 4 | § 249.104 |
| Form 5 | § 249.105 |

The corrections to Rule 16a–2 and Forms 4 and 5 are technical in nature. Rule 16a–2 is amended to remove a quotation mark and the text ''after the first sentence.'' appearing after the second sentence in the introductory text that inadvertently was included in the rule. Additionally, Form 4 and Form 5 are amended to remove the reference to Section 17(a) of the Public Utility Holding Company Act of 1935, which Congress repealed in 2005, that was inadvertently retained in the amended forms.[2]

### Statutory Authority

These technical corrections are being made under the authority set forth in Section 23(a) of the Exchange Act and the Holding Foreign Insiders Accountable Act.[3]

### List of Subjects in 17 CFR Parts 240 and 249

Reporting and recordkeeping requirements, Securities.

### Text of Amendments

For the reasons set out above, we are amending title 17, chapter II of the Code of Federal Regulations as follows:

[1] 15 U.S.C. 78a *et seq.*

[2] *See* Sec. 1263, Energy Policy Act of 2005, Public Law 109–58, 119 Stat. 594 (Aug. 8, 2005).

[3] Sec. 8103 of the National Defense Authorization Act (cited as Holding Foreign Insiders Accountable Act), Public Law 119–60, 139 Stat. 718 (Dec. 18, 2025).

## PART 240—GENERAL RULES AND REGULATIONS, SECURITIES EXCHANGE ACT OF 1934

■ 1. The authority citation for part 240 continues to read, in part, as follows:

**Authority:** 15 U.S.C. 77c, 77d, 77g, 77j, 77s, 77z–2, 77z–3, 77eee, 77ggg, 77nnn, 77sss, 77ttt, 78c, 78c–3, 78c–5, 78d, 78e, 78f, 78g, 78i, 78j, 78j–1, 78k, 78k–1, 78*l*, 78m, 78n, 78n–1, 78o, 78o–4, 78o–10, 78p, 78q, 78q–1, 78s, 78u–5, 78w, 78x, 78dd, 78*ll*, 78mm, 80a–20, 80a–23, 80a–29, 80a–37, 80b–3, 80b–4, 80b–11, 1681w(a)(1), 6801–6809, 6825, 7201 *et seq.,* and 8302; 7 U.S.C. 2(c)(2)(E); 12 U.S.C. 5221(e)(3); 18 U.S.C. 1350; Pub. L. 111–203, 939A, 124 Stat. 1376 (2010); and Pub. L. 112–106, sec. 503 and 602, 126 Stat. 326 (2012), unless otherwise noted.

* * * * *

■ 2. Amend § 240.16a–2 by revising the introductory text to read as follows:

### § 240.16a–2 Persons and transactions subject to section 16.

Any person who is the beneficial owner, directly or indirectly, of more than ten percent of any class of equity securities (''ten percent beneficial owner'') registered pursuant to section 12 of the Act (15 U.S.C. 78*l*), any director or officer of the issuer of such securities, and any person specified in section 30(h) of the Investment Company Act of 1940 (15 U.S.C. 80a–29(h)), including any person specified in § 240.16a–8, shall be subject to the provisions of section 16 of the Act (15 U.S.C. 78p). The rules under section 16(a) of the Act do not apply to ten percent beneficial owners of an issuer that is a foreign private issuer, as defined in Rule 3b–4 (§ 240.3b–4 of this chapter). The rules under section 16 of the Act apply to any class of equity securities of an issuer whether or not registered under section 12 of the Act. The rules under section 16 of the Act also apply to non-equity securities as provided by the Investment Company Act of 1940. With respect to transactions by persons subject to section 16 of the Act:

* * * * *

## PART 249—FORMS, SECURITIES EXCHANGE ACT OF 1934

■ 3. The authority citation for part 249 continues to read, in part, as follows:

**Authority:** 15 U.S.C. 78a *et seq.* and 7201 *et seq.;* 12 U.S.C. 5461 *et seq.;* 18 U.S.C. 1350; Sec. 953(b) Pub. L. 111–203, 124 Stat. 1904; Sec. 102(a)(3) Pub. L. 112–106, 126 Stat. 309 (2012), Sec. 107 Pub. L. 112–106, 126 Stat. 313 (2012), Sec. 72001 Pub. L. 114–94, 129 Stat. 1312 (2015), and secs. 2 and 3 Pub. L. 116–222, 134 Stat. 1063 (2020), unless otherwise noted.

* * * * *

■ 4. Amend Form 4 (referenced in § 249.104) by revising the first page to remove the text '', Section 17(a) of the Public Utility Holding Company Act of 1935''.

**Note:** The text of Form 4 does not, and this amendment will not appear in the Code of Federal Regulations.

■ 5. Amend Form 5 (referenced in § 249.105) by revising the first page to remove the text '', Section 17(a) of the Public Utility Holding Company Act of 1935''.

**Note:** The text of Form 5 does not, and this amendment will not appear in the Code of Federal Regulations.

Dated: May 28, 2026.

**Sherry R. Haywood,**

*Assistant Secretary.*

[FR Doc. 2026–10916 Filed 5–29–26; 8:45 am]

BILLING CODE 8011–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Part 864

[Docket No. FDA–2026–N–5725]

## Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final amendment; final order.

**SUMMARY:** The Food and Drug Administration (FDA) is classifying the von Willebrand factor assay into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the von Willebrand factor assay. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

**DATES:** This order is effective June 1, 2026. The classification was applicable on September 29, 2022.

**FOR FURTHER INFORMATION CONTACT:** Yan Cai, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 3453, Silver Spring, MD 20993–0002, 240–402–1094, *Yan.Cai@fda.hhs.gov.*

**SUPPLEMENTARY INFORMATION:**

### I. Background

Upon request, FDA (the Agency or we) has classified the von Willebrand factor (VWF) assay into class II (special controls), which we have determined will provide a reasonable assurance of safety and effectiveness of the device. In addition, we believe this action will enhance patients' access to beneficial innovation, in part by reducing regulatory burdens by placing the device into a lower device class than the automatic class III assignment.

The automatic assignment of class III occurs by operation of law and without any action by FDA, regardless of the level of risk posed by the new device. Any device that was not in commercial distribution before May 28, 1976, is automatically classified into, and remains within, class III and requires premarket approval unless and until FDA takes an action to classify or reclassify the device (21 U.S.C. 360c(f)(1)). We refer to these devices as ''postamendments devices'' because they were not in commercial distribution prior to the date of enactment of the Medical Device Amendments of 1976, which amended the Federal Food, Drug, and Cosmetic Act (FD&C Act).

FDA may take a variety of actions in appropriate circumstances to classify or reclassify a device into class I or II. We may issue an order finding a new device to be substantially equivalent under section 513(i) of the FD&C Act (21 U.S.C. 360c(i)) to a predicate device that does not require premarket approval. We determine whether a new device is substantially equivalent to a predicate device by means of the procedures for premarket notification under section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and part 807 (21 CFR part 807).

FDA may also classify a device through ''De Novo'' classification, a common name for the process authorized under section 513(f)(2) of the FD&C Act (see also part 860, subpart D (21 CFR part 860, subpart D)). Section 207 of the Food and Drug Administration Modernization Act of 1997 (Pub. L. 105–115) established the first procedure for De Novo classification. Section 607 of the Food and Drug Administration Safety and Innovation Act (Pub. L. 112–144) modified the De Novo classification process by adding a second procedure. A device sponsor may utilize either procedure for De Novo classification.